Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Mundipharma clinical trials
The registry lists 120 studies whose lead sponsor is Mundipharma or one of 13 companies grouped under it. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 13, 2026.
Keep track of what changes. Save the Mundipharma studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Mundipharma.
- Mundipharma Research Limited36 studies →Subsidiary
Something wrong?
- Mundipharma (China) Pharmaceutical Co. Ltd19 studies →Regional office
Something wrong?
- Mundipharma Korea Ltd16 studies →Regional office
Something wrong?
- Mundipharma Research GmbH & Co KG16 studies →Subsidiary
Something wrong?
- Taiwan Mundipharma Pharmaceuticals Ltd.5 studies →Regional office
Something wrong?
- Mundipharma K.K.5 studiesSame company
Something wrong?
- Mundipharma AB4 studiesSame company
Something wrong?
- Mundipharma Pharmaceuticals B.V.3 studies →Regional office
Something wrong?
- Mundipharma Pte Ltd.3 studiesSame company
Something wrong?
- Cinfa Biotech2 studies →Acquired
Something wrong?
- Mundipharma Pharmaceuticals S.L.2 studies →Regional office
Something wrong?
- Mundipharma SAS2 studiesSame company
Something wrong?
- Mundipharma Manufacturing Pte Ltd.2 studies →Subsidiary
Something wrong?
- Mundipharma Pharmaceuticals Sdn. Bhd.1 study →Regional office
Something wrong?
- Mundipharma Oy1 studySame company
Something wrong?
- Mundipharma Medical Company1 study →Subsidiary
Something wrong?
- Mundipharma-EDO GmbH1 study →Subsidiary
Something wrong?
- Mundipharma Pharmaceuticals srl1 study →Regional office
Something wrong?
Focus areas
Conditions Mundipharma leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 120. Browse all 120 →
- Real-world Study of the Effectiveness and Tolerability of Outpatient Titration of OxyContin for the Moderate and Severe Pain in Cancer PatientsNot yet recruitingNCT07869797
Sponsor listed in the registry: Mundipharma (China) Pharmaceutical Co. Ltd
- Rezafungin for Treatment of Pneumocystis Pneumonia in HIV AdultsRecruitingNCT05835479Phase 2
Sponsor listed in the registry: Mundipharma Research Limited
- Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment OptionsActive, not recruitingNCT06794554Phase 2
Sponsor listed in the registry: Mundipharma Research Limited
- Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow TransplantationCompletedNCT04368559Phase 3
Sponsor listed in the registry: Mundipharma Research Limited
- Study of Tinostamustine for Adjuvant Treatment of GlioblastomaCompletedNCT05432375Early Phase 1
Sponsor listed in the registry: Mundipharma Research Limited
- Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of AgeTerminatedNCT05534529Phase 1
Sponsor listed in the registry: Mundipharma Research Limited
- Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.CompletedNCT03345485Phase 1/2
Sponsor listed in the registry: Mundipharma Research Limited
- Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic MalignanciesCompletedNCT02576496Phase 1
Sponsor listed in the registry: Mundipharma Research Limited
- Tinostamustine Conditioning and Autologous Stem CellTerminatedNCT03687125Phase 1/2
Sponsor listed in the registry: Mundipharma-EDO GmbH
- Efficacy and Safety of Oxycodone/Naloxone (Targin®) in Persistent Moderate to Severe Low Back Pain Following NSAIDs TreatmentCompletedNCT03768466Phase 4
Sponsor listed in the registry: Mundipharma Korea Ltd
- Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI TherapyTerminatedNCT04124510Phase 3
Sponsor listed in the registry: Mundipharma Korea Ltd
- Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma PatientsWithdrawnNCT04271839Phase 4
Sponsor listed in the registry: Mundipharma Pharmaceuticals S.L.
- Safety and Effectiveness of Transdermal Buprenorphine in Cancer PainCompletedNCT04315831
Sponsor listed in the registry: Taiwan Mundipharma Pharmaceuticals Ltd.
- Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer PainCompletedNCT03176121Phase 4
Sponsor listed in the registry: Taiwan Mundipharma Pharmaceuticals Ltd.
- A Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Patients With Moderate to Severe Cancer PainCompletedNCT03176199Phase 4
Sponsor listed in the registry: Taiwan Mundipharma Pharmaceuticals Ltd.
- OTR Tablet 10 mg Fasted-state Bioequivalence StudyCompletedNCT03403504Phase 1
Sponsor listed in the registry: Mundipharma (China) Pharmaceutical Co. Ltd
- OTR Tablet 40 mg Fasted-state Bioequivalence StudyCompletedNCT03398278Phase 1
Sponsor listed in the registry: Mundipharma (China) Pharmaceutical Co. Ltd
- OTR Tablet 40 mg Fed-state Bioequivalence StudyCompletedNCT03398330Phase 1
Sponsor listed in the registry: Mundipharma (China) Pharmaceutical Co. Ltd
- OxyNorm® Capsules (Immediate-Release) Pharmacokinetic (PK) StudyCompletedNCT01643772Phase 1
Sponsor listed in the registry: Mundipharma (China) Pharmaceutical Co. Ltd
- Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer PainCompletedNCT01885182Phase 3
Sponsor listed in the registry: Mundipharma (China) Pharmaceutical Co. Ltd
- A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCLCompletedNCT03349333Phase 3
Sponsor listed in the registry: Mundipharma (China) Pharmaceutical Co. Ltd
- OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant PatientsCompletedNCT02880475Phase 1
Sponsor listed in the registry: Mundipharma (China) Pharmaceutical Co. Ltd
- A Study to Evaluate Buprenorphine Transdermal Patch in Chinese Subjects With Moderate to Severe Chronic Cancer PainStatus unknownNCT03967327Phase 3
Sponsor listed in the registry: Mundipharma (China) Pharmaceutical Co. Ltd
- Buprenorphine Transdermal Patches Pharmacokinetic StudyStatus unknownNCT03975010Phase 1
Sponsor listed in the registry: Mundipharma (China) Pharmaceutical Co. Ltd
- Efficacy and Safety of MedifoamⓇ and BetafoamⓇ in Pressure UlcerTerminatedNCT02863263Not applicable
Sponsor listed in the registry: Mundipharma Pte Ltd.
- Trauma Acute Pain Treatment With Methoxyflurane Vaporized (PENTHROX®): Efficacy and Safety Study (MEDITA)CompletedNCT03585374Phase 3
Sponsor listed in the registry: Mundipharma Pharmaceuticals srl
- Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 YearsStatus unknownNCT03387241Phase 3
Sponsor listed in the registry: Mundipharma (China) Pharmaceutical Co. Ltd
- Efficacy and Safety of Penthrox® Combined With a Standard Analgesia (SoC) in Adult Patients Admitted to the Emergency Department With Moderate to Severe Pain Associated With TraumaCompletedNCT03798899Phase 4
Sponsor listed in the registry: Mundipharma SAS
- An Interventional Study for Patient With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through the IV Continuous Infusion.CompletedNCT02660229Phase 4
Sponsor listed in the registry: Mundipharma Korea Ltd
- Flutiform in Treatment of Patients With Asthma in Daily Clinical Practice.WithdrawnNCT02811315
Sponsor listed in the registry: Mundipharma Pharmaceuticals B.V.
- A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPDCompletedNCT01946620Phase 3
Sponsor listed in the registry: Mundipharma Research Limited
- Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible AsthmaCompletedNCT00476073Phase 3
Sponsor listed in the registry: Mundipharma Research Limited
- Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric PatientsCompletedNCT01511367Phase 3
Sponsor listed in the registry: Mundipharma Research Limited
- A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMRTerminatedNCT01821040Phase 3
Sponsor listed in the registry: Mundipharma Research Limited
- A Study to Characterize the Pharmacokinetics and Tolerability of Buprenorphine Patches in Children With Moderate to Severe Mouth PainTerminatedNCT00947466Phase 1/2
Sponsor listed in the registry: Mundipharma Research Limited
- Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.CompletedNCT02063139Phase 2
Sponsor listed in the registry: Mundipharma Research Limited
- Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe AsthmaCompletedNCT00734318Phase 3
Sponsor listed in the registry: Mundipharma Research Limited
- Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible AsthmaCompletedNCT01099722Phase 3
Sponsor listed in the registry: Mundipharma Research Limited
- Study of FLUTIFORM® VS Seretide® in Paediatric Subjects With AsthmaCompletedNCT00475813Phase 3
Sponsor listed in the registry: Mundipharma Research Limited
- Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate AsthmaCompletedNCT00995800Phase 2
Sponsor listed in the registry: Mundipharma Research Limited
- A Study to Assess the Safety and Tolerability of Oxycodone Hydrochloride 50mg/mL Administered as an InfusionTerminatedNCT00626600Phase 3
Sponsor listed in the registry: Mundipharma Research Limited
- An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible AsthmaCompletedNCT00563056Phase 3
Sponsor listed in the registry: Mundipharma Research Limited
- Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime SymptomsCompletedNCT01112644Phase 3
Sponsor listed in the registry: Mundipharma Research GmbH & Co KG
- A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in AsthmaCompletedNCT02753712Phase 3
Sponsor listed in the registry: Mundipharma Research Limited
- A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer TherapyCompletedNCT01438567Phase 3
Sponsor listed in the registry: Mundipharma Research GmbH & Co KG
- Oxycodone-naloxone Prolonged Release Tablets in Relieving Opioid-related ConstipationCompletedNCT00412100Phase 3
Sponsor listed in the registry: Mundipharma Research GmbH & Co KG
- Oxycodone-naloxone in Relieving Opioid-related ConstipationCompletedNCT00412152Phase 3
Sponsor listed in the registry: Mundipharma Research GmbH & Co KG
- A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer PainCompletedNCT00513656Phase 2
Sponsor listed in the registry: Mundipharma Research GmbH & Co KG
- A Randomised, Double Blind, Placebo and Active Controlled, Double Dummy,Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Nonmalignant PainCompletedNCT01971632Phase 3
Sponsor listed in the registry: Mundipharma Research GmbH & Co KG
- OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)CompletedNCT01197261Phase 2
Sponsor listed in the registry: Mundipharma Research GmbH & Co KG